{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T20:48:01Z","timestamp":1772657281309,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.vaccine.2024.05.048","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:41:03Z","timestamp":1717609263000},"page":"126000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7088-867X","authenticated-orcid":false,"given":"Dong-Won","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young","family":"June Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Ae","family":"Suk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hak-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9941-6725","authenticated-orcid":false,"given":"Bo-Kyung","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Kyeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.05.048_b0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a010215","article-title":"The pneumococcus: epidemiology, microbiology, and pathogenesis","volume":"3","author":"Henriques-Normark","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2024.05.048_b0010","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S2214-109X(18)30408-X","article-title":"Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis","volume":"7","author":"McAllister","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2024.05.048_b0015","article-title":"Pneumonia and invasive pneumococcal diseases: the role of pneumococcal conjugate vaccine in the era of multi-drug resistance","volume":"9","author":"Scelfo","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.05.048_b0020","article-title":"Global burden of lower respiratory infections during the last three decades","volume":"10","author":"Safiri","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2024.05.048_b0025","unstructured":"Centers for Disease Control and Prevention. Global Pneumococcal Disease & Vaccine, https:\/\/www.cdc.gov\/pneumococcal\/global.html#:\u223c:text=The%20World%20Health%20Organization%20(WHO,years%20old%20worldwide%20every%20year; 2024 [accessed 27 Jan 2024]."},{"key":"10.1016\/j.vaccine.2024.05.048_b0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1473-3099(05)70083-9","article-title":"Epidemiological differences among pneumococcal serotypes","volume":"5","author":"Hausdorff","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.05.048_b0035","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14760584.2021.1971521","article-title":"Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges","volume":"20","author":"Horn","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.05.048_b0040","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1186\/s12889-022-14051-6","article-title":"Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998\u20132018","volume":"22","author":"Hu","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2024.05.048_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11071816","article-title":"Systematic literature review of the epidemiological characteristics of pneumococcal disease caused by the additional serotypes covered by the 20-valent pneumococcal conjugate vaccine","volume":"11","author":"M\u00e9roc","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2024.05.048_b0050","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s40121-021-00544-1","article-title":"Clinical and economic burden of pneumococcal disease due to serotypes contained in current and investigational pneumococcal conjugate vaccines in children under five years of age","volume":"10","author":"Wasserman","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2024.05.048_b0055","unstructured":"Korea Disease Control and Prevention Agency, https:\/\/www.kdca.go.kr\/index.es?sid=a3; 2023 [accessed 19 Oct 2023]."},{"key":"10.1016\/j.vaccine.2024.05.048_b0060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijid.2020.01.034","article-title":"Evaluation of the effectiveness of pneumococcal conjugate vaccine for children in Korea with high vaccine coverage using a propensity score matched national population cohort","volume":"93","author":"Sohn","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.05.048_b0065","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.vaccine.2023.12.057","article-title":"Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants","volume":"42","author":"Rozenbaum","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.05.048_b0070","unstructured":"Health Insurance Review & Assessment Service. Drug economic evaluation guideline; 2021."},{"key":"10.1016\/j.vaccine.2024.05.048_b0075","unstructured":"Korean Statistical Information Service. Statistical Database, https:\/\/kosis.kr\/eng\/; 2023 [accessed 19 Oct 2023]."},{"key":"10.1016\/j.vaccine.2024.05.048_b0080","unstructured":"Health Insurance Review & Assessment Service. HIRA Bigdata Open portal, https:\/\/opendata.hira.or.kr\/home.do; 2023 [accessed 19 Oct 2023]."},{"key":"10.1016\/j.vaccine.2024.05.048_b0085","unstructured":"National Health Insurance Service. Health Security System, https:\/\/www.nhis.or.kr\/english\/wbheaa02300m01.do; 2024 [accessed 8 May 2024]."},{"key":"10.1016\/j.vaccine.2024.05.048_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijporl.2020.110002","article-title":"The change of prevalence and recurrence of acute otitis media in Korea","volume":"134","author":"Kim","year":"2020","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.vaccine.2024.05.048_b0095","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/21645515.2020.1796426","article-title":"Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea","volume":"17","author":"Kim","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.05.048_b0100","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM199012133232402","article-title":"Seizures and other neurologic sequelae of bacterial meningitis in children","volume":"323","author":"Pomeroy","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.05.048_b0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3343\/alm.2023.43.1.45","article-title":"Serotype distribution and antimicrobial resistance of streptococcus pneumoniae causing invasive pneumococcal disease in korea between 2017 and 2019 after introduction of the 13-valent pneumococcal conjugate vaccine","volume":"43","author":"Kim","year":"2023","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.vaccine.2024.05.048_b0110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(16)00052-7","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study","volume":"4","author":"Moore","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2024.05.048_b0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.05.048_b0120","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia","volume":"21","author":"Black","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.05.048_b0125","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/01.inf.0000232706.35674.2f","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs","volume":"25","author":"Hansen","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.05.048_b0130","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.05.048_b0135","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12913-018-3529-4","article-title":"Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008\u20132014","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.vaccine.2024.05.048_b0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12913-018-3139-1","article-title":"Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008\u20132014","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.vaccine.2024.05.048_b0145","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2257426","article-title":"Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population","volume":"19","author":"Lytle","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.05.048_b0150","unstructured":"Centers for Disease Control and Prevention. Invasive Pneumococcal Disease and 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Coverage Among Children Aged \u226459 Months --- Selected U.S. Regions, 2010--2011. Morbidity and Mortality Weekly Report (MMWR). 2011;60:1477-81."},{"key":"10.1016\/j.vaccine.2024.05.048_b0155","doi-asserted-by":"crossref","first-page":"15833","DOI":"10.1038\/s41598-022-20363-9","article-title":"Impact of national pneumococcal vaccination program on invasive pneumococcal diseases in South Korea","volume":"12","author":"Jung","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.05.048_b0160","article-title":"Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom","volume":"11","author":"Wilson","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.05.048_b0165","unstructured":"Centers for Disease Control and Prevention. Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged <2 years, https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/PCV20-child.html; 2024 [accessed 8 May 2024]."},{"key":"10.1016\/j.vaccine.2024.05.048_b0170","doi-asserted-by":"crossref","first-page":"e8429","DOI":"10.1097\/MD.0000000000008429","article-title":"Disease burden of hospitalized community-acquired pneumonia in South Korea: Analysis based on age and underlying medical conditions","volume":"96","author":"Choi","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2024.05.048_b0175","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.vaccine.2021.01.012","article-title":"Paradoxical health care utilization patterns among children in Korea who did not receive mandatory pneumococcal vaccination","volume":"39","author":"Sohn","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.05.048_b0180","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1017\/S0950268807008564","article-title":"ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged > or = 65 years","volume":"136","author":"Skull","year":"2008","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2024.05.048_b0185","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2214-109X(17)30043-8","article-title":"Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study","volume":"5","author":"Cohen","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2024.05.048_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183191","article-title":"Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7\u201359 months. A matched case-control study","volume":"12","author":"Dom\u00ednguez","year":"2017","journal-title":"PLoS One"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24006169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24006169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T22:08:46Z","timestamp":1737583726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24006169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":38,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0264410X24006169"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126000"}}